Aeterna Zentaris and Ceapro Complete Merger TransactionTORONTO and EDMONTON, Alberta, June 03, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (
NASDAQAEZS) (TSX: AEZS) (“Aeterna” or the “Company”) and Ceapro Inc. (TSX-V: CZO) (OTCQX: CRPOF) (“Ceapro”), two innovative biopharmaceutical development companies, are pleased to announce the successful completion and closing of their all-stock merger of equals transaction (the “Transaction”), which was previously announced by Aeterna and Ceapro in their joint press release of December 14, 2023.
Ceapro Inc. Reports Financial Results for First Quarter 2024 and Provides Corporate Update– Q1 2024 marked by significant advancement of R&D projects focused on avenanthramide Phase 1-2a clinical study and the processing of yeast beta glucan along with the building of pilot scale units for PGX Technology
Ceapro Inc. Reports 2023 Financial Results and Operational Highlights– 2023 marked by Ceapro’s achievement of key milestones and progress toward its next phase of growth
Ceapro Receives Final Court Approval for Merger with Aeterna ZentarisTORONTO and EDMONTON, Alberta, March 28, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (
NASDAQAEZS) (TSX: AEZS) ("Aeterna") and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”) are pleased to announce that the Court of King's Bench of Alberta has issued a final order approving the arrangement described in the previously announced definitive agreement to combine the operations of Ceapro and Aeterna in an all-stock merger of equals transaction (the “Transaction”).
Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical CompanyTORONTO and EDMONTON, Alberta, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (
NASDAQAEZS) (TSX: AEZS) (“Aeterna Zentaris”) and Ceapro Inc. (TSXV: CZO) (OTCQX: CRPOF) (“Ceapro”), two innovative biopharmaceutical development companies, are pleased to announce today that leading independent proxy advisor Institutional Shareholder Services Inc. ("ISS") recommended that both companies’ securityholders vote FOR the all-stock merger of equals transaction (the “Transaction”) pursuant to the terms announced on December 14, 2023.
Ceapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base BusinessEDMONTON, Alberta, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), today provided an update on its progress across its current business.
Ceapro Inc. Announces the Mailing of Meeting Materials in Connection With the Special Meeting of Securityholders to Approve Merger With Aeterna ZentarisEDMONTON, Alberta, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSXV: CZO) (OTCQX: CRPOF) (“Ceapro” or the “Company”) is pleased to announce that it has mailed and filed a management information circular dated February 9, 2024 and related meeting materials (collectively, the “Meeting Materials”) for the special meeting (the “Meeting”) of Securityholders (as defined below) to be held on March 12, 2024, called to consider, among other things, the previously announced all-stock merger of equals transaction pursuant to which it is proposed that, in accordance with the terms announced on December 14, 2023, (i) Aeterna Zentaris Inc. (“Aeterna Zentaris”) will acquire all of the issued and outstanding common shares in the share capital of the Company (the “Shares”) from the shareholders of the Company (the “Shareholders”), in exchange for Aeterna Zentaris common shares (the “Aeterna Zentaris Shares”), and (ii) each of the outstanding options to purchase Shares will cease to represent an option or other right to acquire a Share and will be exchanged for a replacement option allowing their holders (collectively with the Shareholders, the “Securityholders”) to acquire Aeterna Zentaris Shares on similar terms, by way of a statutory plan of arrangement (the “Arrangement”).
Ceapro Inc. Reports 2023 Third Quarter and Nine-Month Financial Results and Operational Highlights– Product development focused on the production of powder formulations of oat beta glucan and avenanthramides for cosmeceuticals market
Ceapro Inc. Enters into Technical Collaboration with NATEX Prozesstechnologie GmbH and Provides Update on the Scale-Up Project for its Patented Pressurized Gas eXpanded (PGX) TechnologyEDMONTON, Alberta, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients and disruptive technologies for healthcare and cosmetic industries, announced today the signing of a technical collaboration with Austria-based NATEX Prozesstechnologie GmbH to accelerate the scale-up of its proprietary PGX Technology towards commercial level. The combination of Ceapro’s natural ingredient processing expertise along with NATEX’ deep knowledge of commercial high-pressure extraction equipment is providing a clear path to sustainable, large-scale production of PGX materials.
Ceapro Inc. Reports 2023 Second Quarter and Six-Month Financial Results and Provides Corporate Update- $5.5 million first six-month 2023 sales vs. $11.7 million for the same period in 2022; sales lagging by one quarter due to stocking campaign by one major customer in 2022 and further Marketplace reorganization
Ceapro Announces Next Phase of Research Collaboration with the Angiogenesis Foundation– New studies to focus on speed of healing and molecular profiling of tissue regeneration induced by oat-derived bioactive products –
Ceapro Announces Results of 2023 Shareholders’ MeetingEDMONTON, Alberta, June 07, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that all proposed Directors were elected to serve for a one-year term at its Annual General and Special Meeting of Shareholders held on June 6, 2023 as per the following results:
Ceapro Inc. Presents Encouraging Results from Research Collaboration Study with McMaster University Evaluating PGX-Processed Yeast Beta Glucan for Interstitial Lung Diseases– Results from the completed Collaborative Health Research Projects (CHRP) study with McMaster University presented at the American Thoracic Society (ATS) International Conference –
Ceapro Announces Positive Findings Demonstrating Oat Derived Beta Glucan and Avenanthramides Promote Wound Healing and Tissue Regeneration– Data presented at 2023 Annual Meeting of the Wound Healing Society showed statistically significant results characterizing the in vivo bioactivity of Ceapro’s oat-derived bioactive products on wound healing and tissue regeneration
Ceapro Inc. Appoints Michel Regnier as Senior Vice President, Technical OperationsExecutive function to oversee Edmonton site technical operations with implementation of Pilot Unit for Pressurized Gas eXpanded (PGX) Technology as key mandate
Ceapro Inc. Reports Record 2022 Financial Results and Operational Highlights– 2022 marks Ceapro’s best performance in Company history with record sales of $18,800,000 compared to $17,200,000 for 2021, representing a 10% increase year over year
Ceapro Announces Data from Research Collaboration with McMaster University to be Presented at the 2023 American Thoracic Society (ATS) International ConferenceOral presentation to highlight unique results from pre-clinical studies demonstrating potential of Ceapro’s yeast beta glucan to reprogram macrophages involved in fibrotic lung diseases
Ceapro Announces Data from Research Collaboration with the Angiogenesis Foundation to be Presented at the 2023 Annual Meeting of the Wound Healing American Society– Oral presentation to highlight unique results from pre-clinical studies characterizing the in vivo bioactivity of Ceapro’s oat-derived bioactive products on angiogenesis, wound healing and tissue regeneration –
Ceapro Inc. Recognized as a Top 50 TSX Venture Exchange CompanyEDMONTON, Alberta, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients and disruptive technologies for healthcare and cosmetic industries, announced today that it has been named as one of the top performers on the TSX Venture Exchange.
Ceapro Announces Grant of Stock OptionsEDMONTON, Alberta, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced the granting of stock options (“options”) to employees, officers and directors of the Company.
Ceapro Inc. Reports 2022 Third Quarter and Nine-Month Financial Results and Operational Highlights– R&D activities focused on the production of Avenanthramides pills for clinical trials and for scale-up of the PGX Technology
Ceapro Inc. Launches Next Phase of Scale Up for its Disruptive PGX Technology to Pursue Product Development for Nutraceutical and Pharmaceutical MarketsEDMONTON, Alberta, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients and disruptive technologies for healthcare and cosmetic industries, announced today the signing of a license agreement with The Governors of the University of Alberta to use designated areas within Agri-Food Discovery Place (AFDP) to further scale up the Company’s disruptive Pressurized Gas eXpanded (PGX) technology in preparation for commercial partnerships.
Ceapro Inc. Announces Positive Data from Bioavailability Studies Evaluating CoQ10 Formulations Impregnated with PGX-Processed CarriersEDMONTON, Alberta, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced positive results from its collaborative project led by Dr. Donna Vine, Professor at the Department of Agriculture, Food and Nutritional Science of University of Alberta.
